tirzepatide surpass SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic

SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized

25.16

★★★★☆4.8 (126)

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program | Cardiovascular Diabetology

24.62

★★★★★4.9 (98)

Tirzepatide Significantly Reduced A1C and Body Weight in People with Type 2 Diabetes in Two Phase 3 Trials from Lilly's SURPASS Program

20.54

★★★★★5.0 (157)

AMRA Used in Tirzepatide Analyses Evaluating the Effect on Muscle Composition via MRI

20.80

★★★★★4.7 (84)

Annals

28.79

★★★★★4.9 (203)

💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What

29.54

★★★★★5.0 (176)

Incidence of mild and severe side effects of tirzepatide in SURPASS 1-5...

20.31

★★★★★4.8 (132)